Status:
ENROLLING_BY_INVITATION
B3 for NMD: Bench to Bedside and Back
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Neuromuscular Disease
Eligibility:
All Genders
18+ years
Brief Summary
Background: Neuromuscular diseases (NMD) represent a broad group of rare genetic and acquired disorders, affecting over 300,000 people in Canada. Given the multiple different NMD subtypes, almost half...
Detailed Description
The B3 for NMD creates a streamlined approach to develop the Bench (preclinical and laboratory characterization) to Bedside (clinical and imaging assessment) and Back (biomarker, diagnostics and thera...
Eligibility Criteria
Inclusion
- Patients or blood relatives of patients classified as having a neuromuscular disease from the following categories:
- Motor Neuron Disease (Amyotrophic Lateral Sclerosis/Spinal Muscular Atrophy)
- Neuropathies
- Neuromuscular Junction Disorders
- Myopathies.
Exclusion
- Patients referred to the neurology clinic without a neuromuscular disorder:
- Central nervous system disorders such as Stroke
- Multiple Sclerosis
- Parkinson's disease
Key Trial Info
Start Date :
May 6 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2033
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04417023
Start Date
May 6 2019
End Date
December 31 2033
Last Update
December 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1Y4E9